Table 1.
Demographic, clinical, and treatment status of study participants, total and by various treatment categories
| Total study group (n =285) |
No current ART (n =91) |
Currently receiving ART (n =194) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Total ART group |
Thymidine analogue nucleoside reverse transcriptase inhibitor (tNRTI) group |
Non-nucleoside reverse transcriptase inhibitor (NNRTI) group |
|||||||
| Total (n =169) | Zidovudine (n =103) |
Stavudine (n =66) |
Total (n =89) | Efavirenz (n =44) |
Nevirapine (n =45) |
||||
| Age in years | 41 (22–68) | 38 (23–58) | 42 (23–67) | 42 (23–67) | 42 (23–67) | 42 (23–60) | 43 (24–59) | 40 (23–59) | 44 (23–68) |
| Female sex | 69 (24) | 33 (36) | 36 (19) | 31 (18) | 20 (19) | 11 (17) | 16 (18) | 7 (16) | 9 (20) |
| Race/ethnicity | |||||||||
| White, non- Hispanic | 163 (57) | 46 (51) | 117 (60) | 98 (58) | 58 (56) | 40 (61) | 54 (61) | 32 (73) | 22 (49) |
| Black, non- Hispanic | 106 (37) | 41 (45) | 65 (34) | 61 (36) | 38 (37) | 23 (35) | 30 (34) | 10 (23) | 20 (44) |
| Othera | 16 (6) | 4 (4) | 12 (6) | 10 (6) | 7 (7) | 3 (4) | 5 (5) | 2 (5) | 3 (7) |
| ART | |||||||||
| Protease inhibitor | 85 (30) | – | 85 (44) | 71 (42) | 31 (30) | 40 (61) | 24 (27) | 11 (25) | 13 (29) |
| Indinavir | 13 (5) | – | 13 (7) | 13 (8) | 3 (3) | 10 (15) | 1 (1) | 0 | 1 (2) |
| Ritonavirb | 51 (18) | – | 51 (26) | 38 (22) | 19 (18) | 19 (29) | 18 (20) | 11 (25) | 7 (16) |
| Saquinavir | 2 (1) | – | 2 (1) | 2 (1) | 1 (1) | 1 (2) | 0 | 0 | 0 |
| Amprenavir | 6 (2) | – | 6 (3) | 5 (3) | 4 (4) | 1 (1) | 1 (1) | 1 (2) | 0 |
| Nelfinavir | 13 (5) | – | 13 (7) | 12 (7) | 3 (3) | 9 (14) | 5 (6) | 0 | 5 (11) |
| Lopinavir/ritonavir | 32 (11) | – | 32 (16) | 20 (12) | 8 (8) | 12 (18) | 16 (18) | 10 (23) | 6 (13) |
| Atazanavir | 18 (6) | – | 18 (9) | 18 (11) | 12 (12) | 6 (9) | 0 | 0 | 0 |
| NNRTI | 89 (31) | – | 89 (46) | 64 (38) | 45 (44) | 19 (29) | 89 (100) | 44 (100) | 45 (100) |
| Efavirenz | 44 (15) | – | 44 (23) | 26 (15) | 17 (17) | 9 (14) | 44 (49) | 44 (100) | – |
| Nevirapine | 45 (16) | – | 45 (23) | 38 (22) | 28 (27) | 10 (15) | 45 (51) | – | 45 (100) |
| tNRTI | 169 (59) | – | 169 (87) | 169 (100) | 103 (100) | 66 (100) | 64 (72) | 26 (54) | 39 (87) |
| Zidovudine | 103 (36) | – | 103 (53) | 103 (61) | 103 (100) | – | 45 (51) | 17 (39) | 28 (62) |
| Stavudine | 66 (23) | – | 66 (34) | 66 (39) | – | 66 (100) | 19 (21) | 9 (20) | 11 (22) |
| Plasma NNRTI level (ng/mL) | – | – | – | – | – | – | – | 1525 (1033–2438) | 5792 (4829–7670) |
| HIV RNA (log10 copies/mL) | 3.0 (1.8–4.0) | 4.2 (3.6–4.6) | 2.3 (1.7–3.2) | 2.4 (1.7–3.2) | 2.3 (1.7–3.2) | 2.5 (1.7–3.3) | 2.1 (1.7–2.8) | 1.8 (1.5–2.7) | 2.3 (1.7–2.9) |
| HIV RNA <400 copies/mL | 112 (39) | 5 (2.9) | 107 (55) | 90 (53) | 54 (52) | 36 (55) | 56 (63) | 32 (73) | 24 (44) |
| CD4+ lymphocytes (cells/mm3) | 428 (268–622) | 432 (296–555) | 425 (252–648) | 435 (253–672) | 423 (253–688) | 451 (256–660) | 434 (260–624) | 390 (187–525) | 534 (327–752) |
| Total cholesterol (mg/dL) | 181 (152–210) | 163 (186–137) | 192 (162–219) | 187 (158–212) | 184 (152–219) | 191 (168–208) | 200 (163–223) | 191 (162–222) | 206 (170–228) |
| Body mass index (kg/m2) | 26 (23–30) | 26 (23–31) | 26 (22–29) | 26 (23–30) | 26 (23–30) | 26 (22–30) | 26 (23–30) | 26 (23–29) | 28 (24–30) |
| Current smoker | 150 (53) | 49 (54) | 101 (52) | 88 (52) | 54 (53) | 34 (52) | 39 (44) | 22 (50) | 17 (38) |
| Heavy smoker (≥20 cigarettes/day) | 78 (52) | 28 (58) | 50 (50) | 42 (48) | 21 (39) | 21 (62) | 19 (49) | 10 (45) | 9 (53) |
| Plasma F2-isopostane (pg/mL) | 37 (27–48) | 36 (26–48) | 38 (27–50) | 37 (27–51) | 33 (24–46) | 39 (30–58) | 33 (26–44) | 38 (29–46) | 32 (24–40) |
Note: Values shown are median (interquartile range) or n (%). ART = antiretroviral therapy; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-NRTI; tNRTI = thymidine analogue NRTI.
a
“Other” includes Hispanic (n = 8), Asian (n = 5), and other self-reported race/ethnicities (n = 3).
b
Includes full dose as well as pharmacologic boosting doses with protease inhibitors other than lopinavir.